Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

8.480 -1.080 (-11.30%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
US Stock Market Movers: Top Gainers and Losers for the Session ↗
Via Chartmill
News headline image
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Away ↗
These biotechs’ valuations are through the roof. 
Via The Motley Fool
Top US Stock Gainers and Losers for Oct. 29, 2026 ↗
Via Chartmill
News headline image
Iovance’s Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing ↗
Iovance Biotherapeutics (NASDAQ:IOVA) reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining... 
Via MarketBeat
Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 Session ↗
Via Chartmill
Premarket Gainers and Losers on Oct. 29, 2026 ↗
Via Chartmill
News headline image
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗
Via Chartmill
Most active stocks in Tuesday's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Iovance Biotherapeutics Stock Was on Fire Today ↗
An influential investment bank resumed its coverage of the company. 
Via The Motley Fool
News headline image
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains ↗
Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter... 
Via MarketBeat
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance (IOVA) Q2 2026 Earnings Call Transcript ↗
Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy. 
Via The Motley Fool
Topics Earnings
News headline image
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? ↗
The healthcare stock is now up more than 130% this year. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Q2 Earnings Call Highlights ↗
Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded... 
Via MarketBeat
Topics Earnings
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results ↗
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.